AIM AIM ImmunoTech Inc.
Price Chart
Executive Summary
AIM ImmunoTech issued a press release highlighting a KOL segment discussing Ampligen for late-stage pancreatic cancer. The release touts positive interim data from the DURIPANC Phase 2 study and the Named Patient Program, showing improvements in progression-free and overall survival versus historical controls. However, this is a forward-looking promotional update with no new regulatory filing, no hard financial data, and no catalyst date beyond an expected mid-2026 report, making it a low-impact event for a micro-cap stock.
Actionable Insight
This is a routine promotional update with no new material data. The stock is a micro-cap with a history of high volatility. Monitor for the mid-2026 DURIPANC report and any regulatory milestones, but do not trade on this release alone.
Key Facts
- Press release announces a KOL Connect segment discussing Ampligen for late-stage pancreatic cancer.
- References positive interim data from the DURIPANC Phase 2 study (with AstraZeneca's Imfinzi) and the Named Patient Program.
- Named Patient Program data shows PFS of 12.6 months vs. 8.6 months historical control and OS of 19.7 months vs. 12.5 months.
- Mid-Year 2026 report, completion of enrollment, and milestones expected in June 2026.
- No new financial data, regulatory filing, or concrete catalyst date provided in the release.
Financial Impact
No financial data disclosed; pre-revenue clinical-stage biotech.
Risk Factors
- Clinical trial failure risk: Ampligen may not show efficacy in larger Phase 3 trials.
- Micro-cap volatility: AIM has a $2M market cap and is prone to large price swings.
- No near-term catalyst: The next milestone is not until June 2026, leaving a long period of uncertainty.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294960 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
2d ago
|
Press Release
| $0.4589 awaiting T+1 | awaiting T+1 | — | $0.4535 (−1.18%) |
|
Jun 4, 2026
6d ago
|
8-K
| $0.5900 $0.5200 | ▼ −11.86% | ▼ −9.27% | $0.4535 (−23.14%) |
|
Jun 1, 2026
9d ago
|
Press Release
| $0.9000 $0.8300 | ▼ −7.78% | ▼ −7.92% | $0.4535 (−49.61%) |
|
May 21, 2026
20d ago
|
8-K
| $0.2400 $0.2400 | · 0.00% | ▲ +0.45% | $0.4535 (−88.96%) |
|
May 21, 2026
20d ago
|
424B5
| $0.2400 $0.2400 | · 0.00% | ▲ +0.45% | $0.4535 (−88.96%) |
|
May 20, 2026
20d ago
|
Press Release
| $0.2500 $0.2400 | ▲ +4.00% | ▲ +4.19% | $0.4535 (−81.40%) |
|
May 19, 2026
21d ago
|
424B5
| $0.2500 $0.2400 | ▼ −4.00% | ▼ −4.19% | $0.4535 (+81.40%) |
|
May 19, 2026
22d ago
|
8-K
| $0.4100 $0.2500 | ▼ −39.02% | ▼ −40.06% | $0.4535 (+10.61%) |
|
May 14, 2026
27d ago
|
8-K
| $0.2600 $0.2500 | ▼ −3.85% | ▼ −2.62% | $0.4535 (+74.42%) |
|
May 14, 2026
27d ago
|
Press Release
| $0.2600 $0.2500 | ▼ −3.85% | ▼ −2.62% | $0.4535 (+74.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access